Santhera Pharmaceuticals Holding AG SPHDF
18.30 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
22.85 Day range 22.85
12.28 52-week range 23.25
- YTD
- +37.08%
- 1 year
- +49.14%
News
seekingalpha.com Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript
proactiveinvestors.co.uk Santhera nears cash break-even as AGAMREE gains traction, Edison says Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note…
seekingalpha.com Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
proactiveinvestors.com eBay heads into Q1 earnings with momentum, but macro clouds loom With eBay Inc (NASDAQ:EBAY, XETRA:EBA) set to report its first-quarter 2026 results on April 29, UBS has bumped its price target on the stock to $110 from...
proactiveinvestors.co.uk Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss…
globenewswire.com Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025 Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
proactiveinvestors.co.uk Santhera wins backing to extend DMD drug AGAMREE to toddlers as young as two Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for…
defenseworld.net Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 35.4% – What’s Next? Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF - Get Free Report)'s stock price was up 35.4% during mid-day trading on Tuesday. The company traded as high as $22.04 and last traded at $22.04.…
proactiveinvestors.co.uk Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the…
proactiveinvestors.com BlackRock shares jump on Q4 earnings, record $14T assets under management BlackRock Inc (NYSE:BLK) reported fourth quarter 2025 earnings that exceeded Wall Street expectations and ended the year with a record $14 trillion in...
proactiveinvestors.co.uk Santhera lands key approval for DMD treatment in Switzerland Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy in patients…
proactiveinvestors.com Santhera lands key approval for DMD treatment in Switzerland Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment...
proactiveinvestors.com Aritzia shares rise as Q3 earnings top expectations Aritzia Inc (TSX:ATZ) shares moved higher as it reported fiscal third quarter earnings that topped analyst expectations, driven by growth in both its retail...
proactiveinvestors.co.uk Santhera shares jump after $205 million Asia-Pacific licensing deal Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy…
proactiveinvestors.com Santhera shares jump after $205 million Asia-Pacific licensing deal Shares in Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) rose 7.4% to CHF 13.14 after the group struck a licensing deal worth up to $205 million plus...
proactiveinvestors.co.uk Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy treatment AGAMREE, handing rights in key…
proactiveinvestors.com Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) has signed a licensing deal worth up to $205 million plus royalties for its Duchenne muscular dystrophy...
seekingalpha.com Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Q2 2025 Earnings Call September 23, 2025 8:00 AM EDT Company Participants Catherine Isted - Chief Financial Officer Shabir Hasham - Chief Medical…